UPDATED: Oracle, Accelrys cater to R&D groups with separate software integrations
Oracle and Accelrys, both of which are key players in the R&D software world, have trotted out updates on important products in their respective tech portfolios.
In an effort to cater to the needs of pharma and CRO partners, Oracle ($ORCL) has integrated its Health Sciences InForm electronic data capture software with its Argus Safety application. By integrating the software products, adverse event data from the InForm system automatically transfers to the Argus Safety software, potentially saving drug developers time and reducing costly errors from manual data entry.
"It also ensures consistent information between the clinical data management and safety systems, which expedites data validation at the end of a trial, ultimately accelerating time to regulatory submission," said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences, in a statement.
Oracle, one of the world's largest software companies, acquired the InForm application in its $685 million buyout of Phase Forward in 2010, and it picked up the Argus tech via an acquistion of Relsys in 2009. Clearly, Oracle continues to integrate parts of the clinical research tech from its buyouts over the past several years.
Accelrys ($ACCL) has announced a separate effort to accelerate research. The San Diego-based company has granted licenses to two components of its lab research and analysis software to research system provider Freeslate. Freestate has the right to sell and support the suite of software tools in the Lab Executive and Analysis (LEA) system.
Accelrys plans to integrate the LEA software, which researchers use for "high throughput research data," with its flagship Enterprise Platform.
Eli Lilly's virtual unit taps Oracle software for clinical trials
Synteract snaps up Oracle software for drug safety monitoring
Oracle, IBM support $100M personalized medicine effort at UPMC
Correction: Accelrys licensed software to Freestate, not the other way around, as we initially reported.